



Endothelial PHD2 deficiency induces nitrate stress *via* suppression of caveolin-1 in pulmonary hypertension

Bin Liu^{1,2}, Yi Peng^{3,4,5}, Dan Yi^{1,2}, Narsa Machireddy^{3,4,5}, Daoyin Dong^{3,4,5}, Karina Ramirez^{1,2}, Jingbo Dai^{3,4,5}, Rebecca Vanderpool⁶, Maggie M. Zhu^{3,4,5}, Zhiyu Dai^{1,2,10} and You-Yang Zhao^{3,4,5,7,8,9,10}

¹Division of Pulmonary, Critical Care and Sleep, Dept of Internal Medicine, University of Arizona, Phoenix, AZ, USA. ²Translational Cardiovascular Research Center, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA. ³Program for Lung and Vascular Biology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. ⁴Section for Injury Repair and Regeneration Research, Stanley Manne Children's Research Institute, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. ⁵Division of Critical Care, Dept of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ⁶College of Medicine Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, USA. ⁷Dept of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ⁸Dept of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ⁹Feinberg Cardiovascular and Renal Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ¹⁰Zhiyu Dai and You-Yang Zhao contributed equally to this article as lead authors and supervised the work.

Corresponding author: You-Yang Zhao (Youyang.zhao@northwestern.edu)



Shareable abstract (@ERSpublications)

Endothelial PHD2 deficiency decreases caveolin-1 expression leading to augmented nitrate stress, which contributes to obliterative pulmonary vascular remodelling and severe pulmonary hypertension <https://bit.ly/3yw48zm>

Cite this article as: Liu B, Peng Y, Yi D, et al. Endothelial PHD2 deficiency induces nitrate stress *via* suppression of caveolin-1 in pulmonary hypertension. *Eur Respir J* 2022; 60: 2102643 [DOI: 10.1183/13993003.02643-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

This article has an editorial commentary:
<https://doi.org/10.1183/13993003.01776-2022>

Received: 19 April 2020
Accepted: 24 June 2022

Abstract

Background Nitrate stress is a characteristic feature of the pathology of human pulmonary arterial hypertension. However, the role of nitrate stress in the pathogenesis of obliterative vascular remodelling and severe pulmonary arterial hypertension remains largely unclear.

Method Our recently identified novel mouse model (*Egln1*^{Tie2Cre}, *Egln1* encoding prolyl hydroxylase 2 (PHD2)) has obliterative vascular remodelling and right heart failure, making it an excellent model to use in this study to examine the role of nitrate stress in obliterative vascular remodelling.

Results Nitrate stress was markedly elevated whereas endothelial caveolin-1 (Cav1) expression was suppressed in the lungs of *Egln1*^{Tie2Cre} mice. Treatment with a superoxide dismutase mimetic, manganese (III) tetrakis (1-methyl-4-pyridyl) porphyrin pentachloride or endothelial *Nos3* knockdown using endothelial cell-targeted nanoparticle delivery of CRISPR-Cas9/guide RNA plasmid DNA inhibited obliterative pulmonary vascular remodelling and attenuated severe pulmonary hypertension in *Egln1*^{Tie2Cre} mice. Genetic restoration of Cav1 expression in *Egln1*^{Tie2Cre} mice normalised nitrate stress, reduced pulmonary hypertension and improved right heart function.

Conclusion These data suggest that suppression of Cav1 expression secondary to PHD2 deficiency augments nitrate stress through endothelial nitric oxide synthase activation, which contributes to obliterative vascular remodelling and severe pulmonary hypertension. Thus, a reactive oxygen/nitrogen species scavenger might have therapeutic potential for the inhibition of obliterative vascular remodelling and severe pulmonary arterial hypertension.

